u/Mission_Direction197

Reddit r/ValueInvesting
· tracked since Jan 2026
Calls
1
Win Rate
100.0%
return
+24.1%
Calls 1 1 Posts tracked · 0.0/day
Calls
7d 0
30d 0
90d 0
Win Rate 100% Long 1 Short 0
Win Rate
7d 100%
30d 0%
90d 0%
Average Return +24.1% Long Return +24.1% Short Return -
Average Return
7d +5.1%
30d -16.2%
90d -27.7%
Visual Insights Log in to see more
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
BRKR 1ST Bruker Bruker
Long
Jan 05
$50.80
+24.1%
Bruker undervalued versus peers with 2026 cyclical recovery catalysts.
Bruker trades at roughly 12x EV/EBITDA, below peers, despite a strong organic growth profile, and should re-rate as pharmaceutical capex and biotech R&D recover. Management's $120M cost-cut program is expected to improve margins in the first half of 2026, with additional benefit from the Project Accelerate initiative for advanced drug development tools. The author argues a 2026 re-rating is likely due to these cyclical and company-specific catalysts.
Diagnostics
REDDIT
Showing 1 of 1 calls · sorted by mentions

u/Mission_Direction197 has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: BRKR.

Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology